From: Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
 | Not corrected for protocols | Corrected for protocols | ||||
---|---|---|---|---|---|---|
 | N | Hazard ratio (95 % CI) | P value | N | Hazard ratio (95 % CI) | P value |
TSIA short (cut-off 1.44 μM) | ||||||
 Low | 79 | 1.00 |  | 73 | 1.00 |  |
 High | 23 | 1. 39 (0.67–2.89) | 0.374 | 22 | 1.34 (0.60–3.01) | 0.477 |
TSIA continuous (cut-off 0.035 μM) | ||||||
 Low | 25 | 1.00 |  | 22 | 1.00 |  |
 High | 75 | 1.19 (0.54–2.60) | 0.671 | 70 | 1.3 (0.53–3.18) | 0.567 |
MTX-Glu1–6 accumulation (cut-off 1935 pmol/109 cells) | ||||||
 High | 29 | 1.00 |  | 29 | 1.00 |  |
 Low | 79 | 2.29 (0.96–5.45) | 0.062 | 72 | 1.73 (0.70–4.27) | 0.232 |
MTX-Glu4–6 accumulation (cut-off 1000 pmol/109 cells) | ||||||
 High | 32 | 1.00 |  | 32 | 1.00 |  |
 Low | 59 | 2.61 (1.07–6.36) | 0.035* | 56 | 2.23 (0.90–5.57) | 0.084 |
DHFR mRNA (cut-off 3.74) | ||||||
 High | 27 | 1.00 |  | 27 | 1.00 |  |
 Low | 18 | 1.50 (0.50–4.47) | 0.466 | 18 | 1.16 (0.37–3.67) | 0.796 |
TS mRNA (cut-off 10) | ||||||
 Low | 34 | 1.00 |  | 33 | 1.00 |  |
 High | 12 | 0.77 (0.21–2.81) | 0.696 | 12 | 0.78 (0.21–3.22) | 0.781 |
FPGS mRNA (cut-off 4.13) | ||||||
 High | 19 | 1.00 |  | 19 | 1.00 |  |
 Low | 23 | 1.17 (0.36–3.83) | 0.798 | 22 | 0.58 (0.16–2.18) | 0.421 |
FPGH mRNA (cut-off 3.17) | ||||||
 High | 16 | 1.00 |  | 15 | 1.00 |  |
 Low | 18 | 1.18 (0.32–4.40) | 0.805 | 18 | 0.80 (0.19–3.33) | 0.764 |
RFC mRNA (cut-off 0.86) | ||||||
 High | 19 | 1.00 |  | 19 | 1.00 |  |
 Low | 25 | 0.70 (0.23–2.19) | 0.544 | 24 | 0.36 (0.10–1.32) | 0.123 |
FPGS activity (cut-off 0.35) | ||||||
 High | 48 | 1.00 |  | 48 | 1.00 |  |
 Low | 12 | 2.32 (0.79–6.80) | 0.125 | 11 | 2.61 (0.88–7.76) | 0.084 |